Literature DB >> 2546965

The neuroendocrine effects of interleukin-2 treatment.

K D Denicoff1, T M Durkin, M T Lotze, P E Quinlan, C L Davis, S J Listwak, S A Rosenberg, D R Rubinow.   

Abstract

Observations of neuropsychiatric changes in patients receiving interleukin-2 (IL-2) led us to examine the effects of IL-2 administration on the stress-related hormones, beta-endorphin, ACTH, cortisol, and CRH. We evaluated 30 cancer patients who received immunotherapy with IL-2 or IL-2 plus lymphokine-activated killer (LAK) cells. Blood samples were taken immediately before and 4 and 8 h after infusion of IL-2 or IL-2 plus LAK cells. IL-2 stimulated increased hormone levels 4 h after infusion compared with those before therapy and with basal levels in normal volunteers at the following magnitudes: beta-endorphin, 10-fold; ACTH, 20-fold; and cortisol, 2-fold. The effect of IL-2 was not altered in patients also receiving LAK cells. An effect of treatment course was noted, with higher stimulated values seen 4 h after IL-2 in the second treatment course compared with those after the first course [change (delta) in beta-endorphin, 101 vs. 11 fmol/mL; delta ACTH, 138 vs. 8 pmol/L; delta cortisol, 414 vs. 218 nmol/L]. We conclude that IL-2 treatment induces the release of neuroendocrine hormones and that a significant increase in hormonal stimulation occurs upon reexposure to IL-2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546965     DOI: 10.1210/jcem-69-2-402

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  Neurochemistry of brain neuroendocrine immune system: signal molecules.

Authors:  A Galoyan
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations.

Authors:  M Dayan; H Zinger; F Kalush; G Mor; Y Amir-Zaltzman; F Kohen; Z Sthoeger; E Mozes
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 3.  Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function.

Authors:  J Fukata; H Imura; K Nakao
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

Review 4.  Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection.

Authors:  Marni N Silverman; Brad D Pearce; Christine A Biron; Andrew H Miller
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

5.  Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures.

Authors:  E Arzt; G Stelzer; U Renner; M Lange; O A Müller; G K Stalla
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 6.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma.

Authors:  H Mönig; A Hauschild; S Lange; U R Fölsch
Journal:  Clin Investig       Date:  1994-12

8.  Suppression of thyroid function by interferon-alpha 2 in man.

Authors:  C J Wiedermann; W Vogel; H Tilg; F J Wiedermann; M Herold; U Zilian; T Wohlfarter; M Gruber; H Braunsteiner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-06       Impact factor: 3.000

Review 9.  Proopiomelanocortin production by epidermal cells: evidence for an immune neuroendocrine network in the epidermis.

Authors:  R S Bhardwaj; T A Luger
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

10.  Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.

Authors:  K M Heaton; G Ju; E A Grimm
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.